Product Description: Biacetyl monoxime (Diacetyl monoxime), a myosin ATPase inhibitor, is a skeletal and cardiac muscle contraction inhibitor. Biacetyl monoxime is also a well-characterized non-competitive inhibitor of chemical and motile activity of skeletal muscle myosin-II. Biacetyl monoxime induces sarcoplasmic reticulum Ca2+ release[1][2][3].
Applications: Metabolism-protein/nucleotide metabolism
Formula: C4H7NO2
References: [1]Ostap EM. 2,3-Butanedione monoxime (BDM) as a myosin inhibitor. J Muscle Res Cell Motil. 2002;23(4):305-8./[2]Xiao YF, et al. Effects of 2,3-butanedione monoxime on blood pressure, myocardial Ca2+ currents, and action potentials of rats. Am J Hypertens. 1995 Dec;8(12 Pt 1):1232-40./[3]Brightman T, et al. 2,3-Butanedione monoxime protects mice against the convulsant effect of picrotoxin by facilitating GABA-activated currents. Brain Res. 1995 Apr 24;678(1-2):110-6./[4]Kohsuke Hashimoto, et al. The myosin ATPase inhibitor, 2,3-butanedione 2-monoxime, prevents protein secretion by the basidiomycete Coprinopsis cinerea. Biotechnol Lett. 2011 Apr;33(4):769-75./[5]R M Phillips, et al. 2,3-Butanedione 2-monoxime (BDM) induces calcium release from canine cardiac sarcoplasmic reticulum. Biochem Biophys Res Commun. 1996 Dec 4;229(1):154-7.
CAS Number: 57-71-6
Molecular Weight: 101.10
Compound Purity: 98.0
Research Area: Metabolic Disease
Solubility: DMSO : 100 mg/mL (ultrasonic)
Target: Myosin;Na+/K+ ATPase
English
Deutsch
